The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833.
 
Yoshiro Nakahara
Honoraria - Asahi Kasei; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen; AstraZeneca Japan; Bristol-Myers Squibb; Ono Pharmaceutical; SRL Diagnostics; Takeda
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst)
 
Reiko Isomura
No Relationships to Disclose
 
Nobuhiko Seki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly Japan; MSD Oncology; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Nihon Medi-Physics
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Katsuhiko Naoki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst)
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences; HUYA Bioscience International; Sysmex
Research Funding - Chugai/Roche (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroaki Okamoto
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)